Algernon Pharmaceuticals   Report issue

For profit Phase 1 Phase 3
Founded: Vancouver Canada (2015)
Status: No NME R&D (2015)

Organization Overview

First Clinical Trial
2020
NCT04318704
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Algernon Pharmaceuticals